Intellia Therapeutics, Inc.
About Intellia Therapeutics, Inc.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $67.7M
- Net income
- -$412.7M
- Total assets
- $842.1M
- Market cap
- $1.9B
- Operating margin
- -651.7%
- Net margin
- -609.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $67.7M
- Operating expenses
- $508.7M
- Operating income
- -$441.0M
- Income tax
- $0
- Net income
- -$412.7M
- EPS (basic)
- $-3.81
- EPS (diluted)
- $-3.81
Balance sheet
- Total assets
- $842.1M
- Current assets
- $527.7M
- Total liabilities
- $170.7M
- Current liabilities
- $103.9M
- Shareholders’ equity
- $671.4M
Cash flow
- Operating cash flow
- -$394.7M
- Investing cash flow
- $228.0M
- Financing cash flow
- $131.5M
- Net cash flow
- -$35.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.9B
- EPS (diluted)
- $-3.81
- Shares outstanding
- 140.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 6, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $412.7M in FY2025.
- Revenue grew 17% from FY2020 to FY2025.
- Trading 52% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Intellia Therapeutics, Inc..
Write a review
News about Intellia Therapeutics, Inc.
News & sentiment via Polygon.io
